imatinib mesylate has been researched along with Eyelid Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anzalone, CL; Cohen, PR; Cortes, JE; Kurzrock, R | 1 |
| Angioï, K; Champigneulle, J; George, JL; Guerci, A; Maalouf, T | 1 |
2 other study(ies) available for imatinib mesylate and Eyelid Diseases
| Article | Year |
|---|---|
Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Blepharoplasty; Drug Administration Schedule; Ecchymosis; Edema; Eyelid Diseases; Female; Humans; Hyperpigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Postoperative Complications; Postoperative Hemorrhage; Preoperative Care; Protein Kinase Inhibitors; Purpura; Pyrimidines; Retrospective Studies; Skin Transplantation | 2014 |
[Palpebral edema secondary to treatment by a specific inhibitor of tyrosine kinase: Glivec. A case report].
Topics: Aged; Antineoplastic Agents; Benzamides; Biopsy; Diagnosis, Differential; Edema; Eyelid Diseases; Eyelids; Female; Humans; Iatrogenic Disease; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Time Factors | 2004 |